| LAHV | leukocyte-associated herpesvirus |
|---|---|
| MDHV | Marek disease herpesvirus |
| STORCH | syphilis, toxoplasmosis, rubella, cytomegalovirus, and herpesvirus |
| human herpesvirus 5 | <virology> Probably the most widespread of the Herpetoviridae group. Infected cells enlarge and have a characteristic inclusion body (composed of virus particles) in the nucleus. Causes disease only in utero (leading to abortion or stillbirth or to various congenital defects), although can be opportunistic in the immunocompromised host. Patients who have been exposed to the virus will remain cytomegalovirus IgG positive. Acronym: CMV (30 Sep 1997) |
|---|---|
| human herpesvirus 6 | A recently discovered human herpesvirus that was found in certain lymphoproliferative disorders, replicates in a number of different types of leukocytes, and is associated with the childhood disease roseola (exanthema subitum). (05 Mar 2000) |
| human herpesvirus 7 | This virus has recently been discovered in association with human lymphocytes; however, a causal relationship to any known disease has not been determined. (05 Mar 2000) |
| suid herpesvirus | The causative agent of pseudorabies. (05 Mar 2000) |
| equine herpesvirus 3 | <virology> A virus causing equine coital exanthema in horses. (05 Mar 2000) |
| equine herpesvirus 4 | <virology> A virus causing equine rhinopneumonitis in horses. (05 Mar 2000) |
| Kaposi sarcoma associated herpesvirus protease | <enzyme> Genbank af010430 Registry number: EC 3.4.21.- Synonym: kshv protease, human herpesvirus 8 protease (26 Jun 1999) |
| aids vaccines | Vaccines or candidate vaccines containing inactivated HIV or some of its component antigens and designed to prevent aids. Some vaccines containing antigens are recombinantly produced. (12 Dec 1998) |
| bacterial vaccines | Suspensions of attenuated or killed bacteria administered for the prevention or treatment of infectious bacterial disease. (12 Dec 1998) |
| cancer vaccines | Vaccines or candidate vaccines designed to prevent or treat cancer. Vaccines are produced using the patient's own whole tumour cells as the source of antigens, or using tumour-specific antigens, often recombinantly produced. (12 Dec 1998) |
| vaccines | Vaccines are microbial preparations of killed or modified microorganisms which can stimulate an immune response in the body in order to prevent future infection with similar microorganism. The smallpox vaccine has totally eliminated the smallpox disease from our planet. (12 Dec 1998) |
| vaccines, attenuated | Live vaccines prepared from microorganisms which have undergone physical adaptation (e.g., by radiation or temperature conditioning) or serial passage in laboratory animal hosts or infected tissue/cell cultures, in order to produce avirulent mutant strains capable of inducing protective immunity. (12 Dec 1998) |
| vaccines, combined | Two or more vaccines in a single dosage form. (12 Dec 1998) |
| vaccines, conjugate | Semisynthetic vaccines consisting of polysaccharide antigens from microorganisms attached to protein carrier molecules. The carrier protein is recognised by macrophages and T-cells thus enhancing immunity. Conjugate vaccines induce antibody formation in people not responsive to polysaccharide alone, induce higher levels of antibody, and show a booster response on repeated injection. (12 Dec 1998) |
| vaccines, DNA | Recombinant DNA vectors encoding antigens administered for the prevention or treatment of disease. The host cells take up the DNA, express the antigen, and present it to the immune system in a manner similar to that which would occur during natural infection. This induces humoral and cellular immune responses against the encoded antigens. The vector is called naked DNA because there is no need for complex formulations or delivery agents; the plasmid is injected in saline or other buffers. (12 Dec 1998) |